Top 5 Stocks to Buy Now
→ Trump’s New Dollar revealed (From Porter & Company) (Ad)tc pixel Free LLY Stock Alerts

Eli Lilly and Company (LLY) Competitors

Eli Lilly and Company logo
$1,098.78 -13.22 (-1.19%)
Closing price 04:00 PM Eastern
Extended Trading
$1,101.49 +2.71 (+0.25%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

LLY vs. AMGN, BIIB, INCY, NVDA, and VKTX

Should you buy Eli Lilly and Company stock or one of its competitors? MarketBeat compares Eli Lilly and Company with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eli Lilly and Company include Amgen (AMGN), Biogen (BIIB), Incyte (INCY), NVIDIA (NVDA), and Viking Therapeutics (VKTX).

How does Eli Lilly and Company compare to Amgen?

Eli Lilly and Company (NYSE:LLY) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

Eli Lilly and Company presently has a consensus price target of $1,227.74, indicating a potential upside of 11.74%. Amgen has a consensus price target of $354.42, indicating a potential upside of 4.98%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, research analysts clearly believe Eli Lilly and Company is more favorable than Amgen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
2 Strong Buy rating(s)
2.87
Amgen
2 Sell rating(s)
15 Hold rating(s)
12 Buy rating(s)
2 Strong Buy rating(s)
2.45

Eli Lilly and Company has higher revenue and earnings than Amgen. Amgen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B15.88$20.64B$28.1539.03
Amgen$36.75B4.96$7.71B$14.3723.49

In the previous week, Eli Lilly and Company had 114 more articles in the media than Amgen. MarketBeat recorded 164 mentions for Eli Lilly and Company and 50 mentions for Amgen. Amgen's average media sentiment score of 1.27 beat Eli Lilly and Company's score of 0.97 indicating that Amgen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
107 Very Positive mention(s)
20 Positive mention(s)
22 Neutral mention(s)
5 Negative mention(s)
9 Very Negative mention(s)
Positive
Amgen
39 Very Positive mention(s)
4 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 0.9% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. Amgen pays an annual dividend of $10.08 per share and has a dividend yield of 3.0%. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. Amgen pays out 70.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Eli Lilly and Company has raised its dividend for 11 consecutive years and Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Eli Lilly and Company has a net margin of 34.98% compared to Amgen's net margin of 20.96%. Amgen's return on equity of 137.41% beat Eli Lilly and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company34.98% 105.77% 23.76%
Amgen 20.96%137.41%13.28%

Eli Lilly and Company has a beta of 0.53, meaning that its share price is 47% less volatile than the broader market. Comparatively, Amgen has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market.

Summary

Eli Lilly and Company beats Amgen on 14 of the 19 factors compared between the two stocks.

How does Eli Lilly and Company compare to Biogen?

Eli Lilly and Company (NYSE:LLY) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

In the previous week, Eli Lilly and Company had 140 more articles in the media than Biogen. MarketBeat recorded 164 mentions for Eli Lilly and Company and 24 mentions for Biogen. Eli Lilly and Company's average media sentiment score of 0.97 beat Biogen's score of 0.78 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
107 Very Positive mention(s)
20 Positive mention(s)
22 Neutral mention(s)
5 Negative mention(s)
9 Very Negative mention(s)
Positive
Biogen
12 Very Positive mention(s)
5 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Eli Lilly and Company has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, Biogen has a beta of 0.2, suggesting that its share price is 80% less volatile than the broader market.

Eli Lilly and Company presently has a consensus price target of $1,227.74, suggesting a potential upside of 11.74%. Biogen has a consensus price target of $217.37, suggesting a potential upside of 10.58%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, equities research analysts clearly believe Eli Lilly and Company is more favorable than Biogen.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
2 Strong Buy rating(s)
2.87
Biogen
1 Sell rating(s)
12 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.55

Eli Lilly and Company has a net margin of 34.98% compared to Biogen's net margin of 13.81%. Eli Lilly and Company's return on equity of 105.77% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company34.98% 105.77% 23.76%
Biogen 13.81%12.83%8.01%

Eli Lilly and Company has higher revenue and earnings than Biogen. Biogen is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B15.88$20.64B$28.1539.03
Biogen$9.89B2.93$1.29B$9.3221.09

82.5% of Eli Lilly and Company shares are owned by institutional investors. Comparatively, 87.9% of Biogen shares are owned by institutional investors. 0.1% of Eli Lilly and Company shares are owned by insiders. Comparatively, 0.3% of Biogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Eli Lilly and Company beats Biogen on 15 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to Incyte?

Incyte (NASDAQ:INCY) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, earnings, media sentiment, institutional ownership and profitability.

Incyte has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

Incyte currently has a consensus price target of $105.10, indicating a potential upside of 7.00%. Eli Lilly and Company has a consensus price target of $1,227.74, indicating a potential upside of 11.74%. Given Eli Lilly and Company's stronger consensus rating and higher possible upside, analysts plainly believe Eli Lilly and Company is more favorable than Incyte.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Incyte
1 Sell rating(s)
13 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.32
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
2 Strong Buy rating(s)
2.87

Eli Lilly and Company has a net margin of 34.98% compared to Incyte's net margin of 26.71%. Eli Lilly and Company's return on equity of 105.77% beat Incyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Incyte26.71% 26.66% 19.77%
Eli Lilly and Company 34.98%105.77%23.76%

97.0% of Incyte shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 16.2% of Incyte shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Eli Lilly and Company has higher revenue and earnings than Incyte. Incyte is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Incyte$5.14B3.82$1.29B$7.0813.87
Eli Lilly and Company$65.18B15.88$20.64B$28.1539.03

In the previous week, Eli Lilly and Company had 142 more articles in the media than Incyte. MarketBeat recorded 164 mentions for Eli Lilly and Company and 22 mentions for Incyte. Eli Lilly and Company's average media sentiment score of 0.97 beat Incyte's score of 0.70 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Incyte
12 Very Positive mention(s)
1 Positive mention(s)
6 Neutral mention(s)
3 Negative mention(s)
0 Very Negative mention(s)
Positive
Eli Lilly and Company
107 Very Positive mention(s)
20 Positive mention(s)
22 Neutral mention(s)
5 Negative mention(s)
9 Very Negative mention(s)
Positive

Summary

Eli Lilly and Company beats Incyte on 14 of the 17 factors compared between the two stocks.

How does Eli Lilly and Company compare to NVIDIA?

NVIDIA (NASDAQ:NVDA) and Eli Lilly and Company (NYSE:LLY) are related large-cap companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

NVIDIA pays an annual dividend of $1.00 per share and has a dividend yield of 0.5%. Eli Lilly and Company pays an annual dividend of $6.92 per share and has a dividend yield of 0.6%. NVIDIA pays out 15.3% of its earnings in the form of a dividend. Eli Lilly and Company pays out 24.6% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. NVIDIA has increased its dividend for 1 consecutive years and Eli Lilly and Company has increased its dividend for 11 consecutive years. Eli Lilly and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

NVIDIA has a beta of 2.22, indicating that its share price is 122% more volatile than the broader market. Comparatively, Eli Lilly and Company has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market.

NVIDIA has higher revenue and earnings than Eli Lilly and Company. NVIDIA is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
NVIDIA$215.94B23.61$120.07B$6.5332.26
Eli Lilly and Company$65.18B15.88$20.64B$28.1539.03

NVIDIA has a net margin of 62.97% compared to Eli Lilly and Company's net margin of 34.98%. Eli Lilly and Company's return on equity of 105.77% beat NVIDIA's return on equity.

Company Net Margins Return on Equity Return on Assets
NVIDIA62.97% 96.94% 72.16%
Eli Lilly and Company 34.98%105.77%23.76%

65.3% of NVIDIA shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 3.9% of NVIDIA shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

NVIDIA currently has a consensus target price of $305.67, suggesting a potential upside of 45.08%. Eli Lilly and Company has a consensus target price of $1,227.74, suggesting a potential upside of 11.74%. Given NVIDIA's stronger consensus rating and higher probable upside, research analysts clearly believe NVIDIA is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
NVIDIA
0 Sell rating(s)
3 Hold rating(s)
48 Buy rating(s)
3 Strong Buy rating(s)
3.00
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
2 Strong Buy rating(s)
2.87

In the previous week, NVIDIA had 162 more articles in the media than Eli Lilly and Company. MarketBeat recorded 326 mentions for NVIDIA and 164 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.97 beat NVIDIA's score of 0.95 indicating that Eli Lilly and Company is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
NVIDIA
207 Very Positive mention(s)
33 Positive mention(s)
50 Neutral mention(s)
29 Negative mention(s)
5 Very Negative mention(s)
Positive
Eli Lilly and Company
107 Very Positive mention(s)
20 Positive mention(s)
22 Neutral mention(s)
5 Negative mention(s)
9 Very Negative mention(s)
Positive

Summary

NVIDIA beats Eli Lilly and Company on 13 of the 20 factors compared between the two stocks.

How does Eli Lilly and Company compare to Viking Therapeutics?

Eli Lilly and Company (NYSE:LLY) and Viking Therapeutics (NASDAQ:VKTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

Eli Lilly and Company has higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eli Lilly and Company$65.18B15.88$20.64B$28.1539.03
Viking TherapeuticsN/AN/A-$359.64M-$4.14N/A

Eli Lilly and Company has a beta of 0.53, indicating that its share price is 47% less volatile than the broader market. Comparatively, Viking Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market.

Eli Lilly and Company presently has a consensus target price of $1,227.74, suggesting a potential upside of 11.74%. Viking Therapeutics has a consensus target price of $93.60, suggesting a potential upside of 208.10%. Given Viking Therapeutics' higher probable upside, analysts plainly believe Viking Therapeutics is more favorable than Eli Lilly and Company.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Eli Lilly and Company
1 Sell rating(s)
4 Hold rating(s)
23 Buy rating(s)
2 Strong Buy rating(s)
2.87
Viking Therapeutics
1 Sell rating(s)
3 Hold rating(s)
8 Buy rating(s)
2 Strong Buy rating(s)
2.79

Eli Lilly and Company has a net margin of 34.98% compared to Viking Therapeutics' net margin of 0.00%. Eli Lilly and Company's return on equity of 105.77% beat Viking Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Eli Lilly and Company34.98% 105.77% 23.76%
Viking Therapeutics N/A -71.31%-65.35%

82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by company insiders. Comparatively, 5.3% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Eli Lilly and Company had 159 more articles in the media than Viking Therapeutics. MarketBeat recorded 164 mentions for Eli Lilly and Company and 5 mentions for Viking Therapeutics. Eli Lilly and Company's average media sentiment score of 0.97 beat Viking Therapeutics' score of 0.39 indicating that Eli Lilly and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Eli Lilly and Company
107 Very Positive mention(s)
20 Positive mention(s)
22 Neutral mention(s)
5 Negative mention(s)
9 Very Negative mention(s)
Positive
Viking Therapeutics
1 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Eli Lilly and Company beats Viking Therapeutics on 12 of the 15 factors compared between the two stocks.

Get Eli Lilly and Company News Delivered to You Automatically

Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

LLY vs. The Competition

Export
MetricEli Lilly and CompanyLarge Cap Pharma IndustryMedical SectorNYSE Exchange
Market Cap$1.05T$302.67B$6.40B$23.18B
Dividend Yield0.62%2.78%2.67%4.07%
P/E Ratio39.0327.0424.5131.62
Price / Sales15.884.84553.78103.59
Price / Cash44.2413.1843.9424.31
Price / Book39.147.7210.704.68
Net Income$20.64B$11.61B$3.57B$1.08B
7 Day Performance-5.42%-3.09%0.56%-0.26%
1 Month Performance11.13%0.48%3.57%2.18%
1 Year Performance40.10%18.05%28.49%24.66%

Eli Lilly and Company Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
LLY
Eli Lilly and Company
4.4327 of 5 stars		$1,098.78
-1.2%		$1,227.74
+11.7%		+40.4%$1.05T$65.18B39.0350,000
AMGN
Amgen
4.3356 of 5 stars		$355.20
+0.3%		$354.12
-0.3%		+17.8%$191.70B$36.75B24.7231,500
BIIB
Biogen
3.8626 of 5 stars		$200.05
+0.0%		$217.26
+8.6%		+57.0%$29.53B$9.89B21.467,500
INCY
Incyte
3.9168 of 5 stars		$108.53
+0.6%		$105.10
-3.2%		+43.9%$21.68B$5.14B15.332,844
NVDA
NVIDIA
4.9959 of 5 stars		$205.19
+0.2%		$305.67
+49.0%		+42.0%$4.97T$215.94B31.4242,000

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NYSE:LLY) was last updated on 6/18/2026 by MarketBeat.com Staff.
From Our Partners
Hopeless About Retirement? Hopeless and Helpless Aren’t the Same Thing
Your retirement date didn't move once - it moved slowly, then repeatedly, until the shift felt normal. That's ...
Golden Portfolio | Sponsoredtc pixel
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
A 3M Oz. Historical Gold Resource And A Market That Hasn't Caught Up
One Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...
Wall Street Logic | Sponsoredtc pixel
How to play the Biggest IPO in stock market history!
SpaceX is eyeing a near-$2 trillion IPO valuation, and retail investors are already lining up - but early insi...
InvestPub | Sponsoredtc pixel
This is the worst news for stocks in 50 years
Goldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...
TradeSmith | Sponsoredtc pixel
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...
Profits Run | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel